marked.bio

multi-kinase inhibitor · small molecule

lenvatinib

10 active trials across 12 of our biomarkers, targeting VEGFR (multi-kinase). Not approved for any biomarker on marked.bio yet.

Also known as E7080, Lenvima.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
MSI-H / dMMR 3 4 Phase 2
RET fusion or mutation 3 4 Phase 4
EGFR exon 19 deletion / L858R 2 4 Phase 2
HER2-low / ultralow (IHC 1+ or 2+/ISH-) 2 2 Phase 2
ALK fusion 1 3 Phase 1/2
BRAF V600E 1 1 Phase 4
IDH1/2 mutation 1 1 Phase 2
NTRK1/2/3 fusion 1 1 Phase 4
FGFR2 fusion or rearrangement 0 1 –
FGFR3 alteration (mutation or fusion) 0 1 –
KRAS G12C 0 1 –
ROS1 fusion 0 1 –

Sponsors

Industry sponsors leading active biomarker-selected trials of lenvatinib.

  1. MSD (Merck & Co.) 1
  2. Eisai 1

Trials

10 of 17 trials shown

  1. Genotype-Driven Neoadjuvant Therapy for Locally Advanced Thyroid Cancer: A Real-World Cohort Study

    Not yet recruiting Phase 4 Fujian Medical University Started 2025Primary completion 2027-12 NCT07010393

    dabrafenib FDA EUtrametinib FDA EUselpercatinibpralsetiniblenvatiniblarotrectinibanlotinibpembrolizumabsintilimabcabozantinibBemosuzumab

    BRAF V600E mutation

    BRAF V600ERET fusion or mutationNTRK1/2/3 fusionThyroid Neoplasms

  2. A Prospective, Single-center, Non-randomized, Interventional Study on the Effectiveness and Safety of Combined Immunotargeted Therapy in Patients With Metastatic Non-small Cell Cancer With a RET Gene Translocation

    Recruiting Phase 3 EuroCityClinic Started 2026Primary completion 2028-08 NCT07809256

    lenvatinibpembrolizumab

    Have a confirmed RET gene rearrangement, identified using a validated molecular test, such as next-generation sequencing (NGS), p…

    RET fusion or mutationNSCLC (Non-small Cell Lung Cancer)R

  3. Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib as First-Line Therapy for Advanced HER2-Positive/HER2-Low Biliary Tract Cancer

    Recruiting Phase 2 Peking Union Medical College Hospital Started 2026Primary completion 2027-04 NCT07670273

    trastuzumab rezetecanadebrelimablenvatinib

    HER2 positive (IHC 3+ or IHC 2+ and FISH detects HER2/CEP17 ≥ 2.0), HER2 low expression (IHC 2+/FISH- or IHC 1+);

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Biliary Tract Neoplasms Immunotherapy

  4. Phase II Study of Trastuzumab Rezetecan Combined With Adebrelimab and Lenvatinib in Advanced HER2-Positive/Low-Expression Biliary Tract Cancer

    Recruiting Phase 2 Peking Union Medical College Hospital Started 2026Primary completion 2027-04 NCT07704177

    trastuzumab rezetecanadebrelimablenvatinib

    HER2 positive (IHC 3+ or IHC 2+ and FISH detects HER2/CEP17 ≥ 2.0), HER2 low expression (IHC 2+/FISH- or IHC 1+)

    HER2-low / ultralow (IHC 1+ or 2+/ISH-)Biliary Tract Neoplasms Immunotherapy

  5. Immunotherapy Combined With Anti-angiogenic Therapy and Chemotherapy for Potentially Resectable MSI-H, dMMR Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

    Not yet recruiting Phase 2 The First Affiliated Hospital with Nanjing Medical University Started 2025Primary completion 2028-12 NCT07151209

    iparomlimab and tuvonralimablenvatinib

    …therapy Combined With Anti-angiogenic Therapy and Chemotherapy for Potentially Resectable MSI-H, dMMR Locally Advanced Gastric or Gastroesophageal Junction Adenocarcinoma

    MSI-H / dMMRGastric or Gastroesophageal Junction Adenocarcinoma

  6. An Exploratory Study on the Use of Ivosidenib for the Precise Treatment of Advanced Biliary Tract Malignancies With IDH1 Mutations in the Later Line of Therapy.

    Recruiting Phase 2 Peking Union Medical College Hospital Started 2024Primary completion 2026-10 NCT07282262

    ivosidenib FDA EUlenvatinibPD-1/PD-L1 inhibitor

    Genetic Mutation: Presence of an IDH1 mutation confirmed by genetic testing.

    IDH1/2 mutationBiliary Tract Cancer

  7. The Efficacy and Safety of IBI363 in Solid Tumors

    Recruiting Phase 1/2 Hunan Province Tumor Hospital Started 2023Primary completion 2026-12 NCT06081907

    IBI363lenvatinib

    …F: Patients with histological or cytological confirmation of advanced NSCLC who harboring EGFR mutation and failed standard treatment.

    EGFR exon 19 deletion / L858RALK fusionRET fusion or mutationStatus may be outdated, last updated 2024-05-30Advanced Solid Tumor

  8. A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients

    Active, not recruiting Phase 2 Shanghai Chest Hospital Started 2021Primary completion 2025-12 NCT05078931

    pembrolizumablenvatinib

    Have confirmation with sensitizing EGFR mutations, either DEL19 or L858R

    EGFR exon 19 deletion / L858RNSCLC

  9. Pembrolizumab Plus Lenvatinib in Combination With Belzutifan in Solid Tumors (MK-6482-016)

    Active, not recruiting Phase 2 MSD (Merck & Co.) Started 2021Primary completion 2027-03 NCT04976634

    pembrolizumab FDA EUBelzutifanlenvatinib

    Colorectal cancer (CRC) (non-microsatellite instability-high \[non-MSI-H\]/deficient mismatch repair \[dMMR\])

    MSI-H / dMMRNeoplasm Malignant

  10. A Study of E7386 in Combination With Other Anticancer Drug(s) in Participants With Solid Tumor

    Active, not recruiting Phase 1/2 Eisai Started 2019Primary completion 2027-03 NCT04008797

    E7386lenvatinibdoxorubicinpaclitaxel

    Immune checkpoint inhibitor for participants with microsatellite instability-high (MSI-H) CRC

    MSI-H / dMMREndometrial Neoplasms, Neoplasms, Carcinoma, Hepatocellular, Liver Neoplasms